Allstate (ALL) Reports Q2 Earnings: What Key Metrics Have to Say

31.07.25 02:30 Uhr

Werte in diesem Artikel
Aktien

168,20 EUR 1,20 EUR 0,72%

71,50 EUR -6,50 EUR -8,33%

Indizes

PKT PKT

17.425,0 PKT -71,0 PKT -0,41%

6.347,2 PKT -15,7 PKT -0,25%

Allstate (ALL) reported $16.78 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 6.1%. EPS of $5.94 for the same period compares to $1.61 a year ago.The reported revenue represents a surprise of -2.91% over the Zacks Consensus Estimate of $17.28 billion. With the consensus EPS estimate being $3.32, the EPS surprise was +78.92%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Allstate performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Property-Liability - Combined Ratio: 91.1% compared to the 97.2% average estimate based on eight analysts.Property-Liability - Loss Ratio: 70.3% compared to the 75.2% average estimate based on seven analysts.Property-Liability - Expense Ratio: 20.8% versus the seven-analyst average estimate of 21.8%.Allstate Protection - Homeowners Insurance - Combined Ratio: 102% versus 103.8% estimated by five analysts on average.Property-Liability- Net Premiums Earned: $14.35 billion compared to the $14.55 billion average estimate based on eight analysts. The reported number represents a change of +7.6% year over year.Property-Liability- Other Revenue: $504 million compared to the $496.78 million average estimate based on seven analysts. The reported number represents a change of +14.3% year over year.Property-Liability- Net Investment Income: $687 million versus the seven-analyst average estimate of $742.78 million. The reported number represents a year-over-year change of +6.8%.Allstate Health and Benefits- Accident and health insurance premiums and contract charges: $235 million versus $350.91 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -50.4% change.Corporate and Other- Net Investment Income: $37 million compared to the $24.9 million average estimate based on six analysts. The reported number represents a change of +76.2% year over year.Revenues- Property-liability: $15.35 billion versus $15.76 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +7.2% change.Allstate Health and Benefits- Net investment income: $5 million versus the six-analyst average estimate of $19.98 million. The reported number represents a year-over-year change of -80%.Allstate Protection- Net Premiums Earned- Homeowners: $3.77 billion versus the five-analyst average estimate of $3.86 billion. The reported number represents a year-over-year change of +15.9%.View all Key Company Metrics for Allstate here>>>Shares of Allstate have returned -3.1% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.#1 Semiconductor Stock to Buy (Not NVDA)The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Allstate Corporation (ALL): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Allstate und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Allstate

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Allstate

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Allstate Corp.

Wer­bung

Analysen zu Allstate Corp.

DatumRatingAnalyst
15.01.2019Allstate BuyCompass Point
11.08.2017Allstate OverweightBarclays Capital
03.04.2017Allstate Mkt PerformFBR & Co.
09.05.2016Allstate BuyDeutsche Bank AG
10.08.2015Allstate BuyDeutsche Bank AG
DatumRatingAnalyst
15.01.2019Allstate BuyCompass Point
11.08.2017Allstate OverweightBarclays Capital
09.05.2016Allstate BuyDeutsche Bank AG
10.08.2015Allstate BuyDeutsche Bank AG
04.08.2015Allstate OverweightBarclays Capital
DatumRatingAnalyst
03.04.2017Allstate Mkt PerformFBR & Co.
05.08.2015Allstate NeutralCompass Point
04.08.2015Allstate Sector PerformRBC Capital Markets
07.05.2015Allstate NeutralCompass Point
31.10.2014Allstate NeutralCompass Point
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Allstate Corp. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen